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Mitochondrial carriers are believed widely to be dimers both in
structure and function. However, the structural fold is a barrel of six
transmembrane -helices without an obvious dimerisation interface.
Here, we show by negative dominance studies that the yeast mito-
chondrial ADP/ATP carrier 2 from Saccharomyces cerevisiae (AAC2) is
functional as a monomer in the mitochondrial membrane. Adenine
nucleotide transport by wild-type AAC2 is inhibited by the sulfhydryl
reagent 2-sulfonatoethyl-methanethiosulfonate (MTSES), whereas
the activity of a mutant AAC2, devoid of cysteines, is unaffected.
Wild-type and cysteine-less AAC2 were coexpressed in different
molar ratios in yeast mitochondrial membranes. After addition of
MTSES the residual transport activity correlated linearly with the
fraction of cysteine-less carrier present in the membranes, and so
the two versions functioned independently of each other. Also, the
cysteine-less and wild-type carriers were purified separately, mixed in
defined ratios and reconstituted into liposomes. Again, the residual
transport activity in the presence of MTSES depended linearly on the
amount of cysteine-less carrier. Thus, the entire transport cycle for
ADP/ATP exchange is carried out by the monomer.
mechanism  membrane protein  negative dominance studies 
oligomeric state  transport
M itochondrial carriers are believed widely to exist andfunction as homo-dimers (1–23). However, structural data
are inconsistent with biochemical and biophysical studies that
have been used to provide support for the existence of dimers in
membranes and in detergents. First, the projection structure of
the mitochondrial yeast ADP/ATP carrier demonstrated that the
structural fold consists of six transmembrane (TM) -helices
rather than an intercalated bundle of twelve -helices (24).
Second, there are no extensive protein-protein interfaces be-
tween neighboring carriers in the crystals, as would be expected
for proteins that require cooperative interaction to function (25).
Third, the density distribution had 3-fold pseudo symmetry in
agreement with the 3-fold sequence repeats found in all mito-
chondrial carriers (26, 27). Fourth, the substrate translocation
pathway appeared to be in the centre of the protein, rather than
at the interface between two monomers (24). Fifth, although the
proteins formed two-dimensional crystals of dimers in rows in
both the P22121 and P2 crystal forms (24), it was monomeric in
detergent before crystal formation (28). Sixth, the atomic struc-
ture of the bovine ADP/ATP carrier in detergent determined by
x-ray crystallography of P21212 and C2221 crystal forms showed
that the structural fold was a six--helical bundle with three
additional short -helices in the mitochondrial matrix (13).
Seventh, the P21212 crystal did not contain pairs of interacting
proteins with the same orientation (13), but the C2221 crystal
contained two types of dimers, one of which has been proposed
to be biologically significant (11, 29). However, all of the
protein-protein interactions in these crystals are mediated by
proteins with different orientations, and so the dimers probably
have been formed during crystallization. Eight, the pseudo
3-fold axis of symmetry in the C2221 crystal is at 10° to the
plane of themembrane, which is incompatible with sequence and
structural conservation of symmetry, and the density distribution
in the projection structure of AAC3 (24). Ninth, homo-dimer
formation in the C2221 crystal is mediated entirely by cardio-
lipins (11), and it is difficult to see how this type of interaction
could provide a means for cooperativity and for the formation
of specific homo-dimers in the presence many structurally re-
lated but functionally different carriers in mitochondrial mem-
branes. Tenth, as with the P22121 and P2 crystals (24), both
monomers of the dimer bind atractylosides and so they are in the
same rather than in the opposed state. Finally, the dimer
interface in the P22121 crystals (24) differs from that in theC2221
crystal (11), and so there is no consistent interaction interface.
Thus, there is no structural explanation of how the dimers might
form. Recently, we have shown that the yeast ADP/ATP carrier
is monomeric in a wide range of detergents (28), but the question
of whether themonomers are associated into homo-dimers in the
membrane has remained unresolved.
Here, we have investigated by negative dominance studies
whether a yeast ADP/ATP carrier in the mitochondrial membrane
needs to be associated to function. This approach is based on dimers
becoming dysfunctional when one protomer is disabled. It has been
used to show that lactose permease LacY functions as a monomer
(30), that the small drug transporter EmrE functions as an oligomer
(31), and that maltoporin functions as a trimer with three distinct
selectivity filters (32, 33). To establish the functional interaction
between monomers, it must be possible to inactivate one protomer
and to leave the secondmonomer unmodified and active. The yeast
ADP/ATP carrier can be inactivated by sulfhydryl reagents, but
replacement of its four cysteine residues by alanine provides a fully
active carrier (34). Wild-type and cysteine-less ADP/ATP carriers
were coexpressed in various molar ratios in mitochondrial mem-
branes. The function of the cysteine-less ADP/ATP carrier 2 from
Saccharomyces cerevisiae (AAC2) was unaffected by the inhibition
of the coexpressed wild-type carriers, and so the two forms function
independently. In addition, the cysteine-less and wild-type carriers
were purified, mixed in defined ratios and reconstituted into
liposomes. After addition of the sulfhydryl reagent, the residual
transport rate correlated linearly with the fraction of cysteine-less
AAC2, indicating that there is no functional association between
AAC2 protomers. Thus, the yeast mitochondrial ADP/ATP carri-
ers function as monomers in membranes.
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Results
The yeast ADP/ATP carrier AAC2 has cysteines at residues 73,
244, 271, and 288 in matrix -helix h12, in TM -helix H5, in
matrix -helix h56, and in TM -helix H6, respectively (Fig. 1).
Transport activity of AAC2 can be inhibited by the sulfhydryl
reagent eosin-5-maleimide, whereas the function of a cysteine-
less AAC2, in which the cysteines were replaced by alanines, is
unaffected (34). Similarly, the transport of ADP by wild-type
AAC2 was inhibited fully by the membrane-impermeable sulf-
hydryl reagent, 2-sulfonatoethyl-methanethiosulfonate
(MTSES), whereas ADP transport by the cysteine-less form was
unaffected (Fig. 2C). The effect of MTSES on the transport
activity was attributed mainly to Cys-73 and Cys-271, and to a
much lesser extent to Cys-244 and Cys-288 [see supporting
information (SI) Figs. 5 and 6 and SI Results].
Coexpression of Cysteine-Less and Wild-Type AAC2 in Mitochondrial
Membranes. The cysteine-less and wild-type AAC2 were ex-
pressed at different and defined molar ratios in mitochondrial
membranes (Fig. 2), and the effect of MTSES on transport
activity was determined (Fig. 2 and 3). If the two versions of
AAC2 functioned independently, the residual transport activity
after addition of MTSES would correlate linearly with the
fraction of cysteine-less AAC2 (Fcl) according to:
Vwith MTSES FclVwithout MTSES, [1]
where Vwith MTSES and Vwithout MTSES are the specific initial
transport rates in presence and absence of MTSES, respectively.
If two functional monomers had to dimerize to transport, both
homo-dimers of the wild-type AAC2 and hetero-dimers of
wild-type and cysteine-less protomers would be affected by the
addition of MTSES. If so, the residual specific initial uptake rate
in the presence of MTSES would depend on the square of
the fraction of the cysteine-less AAC2 (see SI Fig. 7 for an
explanation).
Vwith MTSES Fcl2Vwithout MTSES. [2]
Cysteine-less and wild-type AAC2 were expressed from eight
different expression cassettes, each consisting of a constitutive
promoter followed by a version of the aac2 gene and a tran-
scription terminator. The promoters were Paac2, the promoter
of aac2, and Ppic2, the promoter of the mitochondrial phosphate
carrier from S. cerevisiae. Each version of AAC2 was expressed
with and without a six-histidine tag and a protease Xa cleavage
site. Also, the wild-type and cysteine-less AAC2 were coex-
pressed from four tandem cassettes with the same promoter in
both cassettes, so as to provide simultaneous expression of
the two versions of AAC2. In the latter experiments, either the
wild-type or the cysteine-less version of AAC2 was tagged. The
tagged version was less mobile than the untagged version in
sodium-dodecylsulfate polyacrylamide gels, allowing the two
forms to be resolved and the amounts of wild-type and cysteine-
less AAC2 expressed in the membrane to be quantified by
Western blot analysis.
The tagged and untagged versions of wild-type and cysteine-
less AAC2 were expressed in mitochondrial membranes sepa-
rately or in all combinations (Fig. 2 A and B). The cysteine-less
AAC2 was produced at similar levels to the wild-type AAC2, and
the Ppic2 promoter was stronger than the Paac2 promoter. The
average expression levels of the His-tagged versions were 77%
that of the untagged versions. The fraction of cysteine-less
carriers coexpressed by the tandem constructs was 0.843 for
Paac2-XCLPaac2-HWT, 0.838 for Ppic2-XCLPpic2-HWT,
0.382 for Paac2-XWTPaac2-HCL, and 0.315 for Ppic2-
XWTPpic2-HCL (Fig. 2 A and B). The molar ratio was not
affected by the promoter or by the version of AAC2 and the
presence of the His-tag was the main factor that reduced
expression in both single and tandem constructs.
The specific initial uptake rate of ADP was determined in
mitochondrial membranes in the presence and absence of
MTSES. In the absence of MTSES, it had a similar value
Fig. 1. Stereoviewof the comparative structuralmodel of the yeast ADP/ATP
carrier AAC2. The model (courtesy of A. Robinson, Medical Research Council,
Cambridge, U.K.) is based on coordinates of the bovine ADP/ATP carrier (13)
and the alignment in SI Fig. 4. The structure is shown in cartoon and surface
representation as generated by PyMOL (DeLano Scientific, Palo Alto, CA). The
TM -helices are numbered according to their appearance in the sequence.
Thematrix helices are preceded by h and named by the two TM -helices they
connect (13). The four encircled cysteines are numbered by their order in the
sequence and they are shown as van der Waals spheres.
Fig. 2. The transport activities in the presence and absence of MTSES of
untagged and/or His-tagged AAC2 versions expressed individually or in com-
binations. (A) Coomassie blue-stained sodium-dodecylsulfate polyacrylamide
gel of isolated mitochondrial membranes with7.5 g of protein loaded per
lane. (B) Western blot of the same samples with -AAC2 antibody with0.75
g of protein loaded per lane. Closed and open arrow heads indicate the
positions of theHis-tagged anduntaggedAAC2, respectively. (C) The effect of
MTSES on the specific initial uptake rate of wild-type and cysteine-less AAC2,
expressed individually or in combinations. The black and the white bars
indicate the specific initial uptake rate in the absence and the presence of
MTSES, respectively. Paac2 and Ppic2 are the promoters. X and H indicate
untagged and His-tagged AAC2, respectively, and CL and WT indicate the
cysteine-less and wild-type AAC2, respectively.








(average of 20.6 2.7 nmol min1 mg1 of AAC2) for all version
of AAC2 whether they were expressed as single or as tandem
combinations (Fig. 2C). The average specific initial uptake rate
for the cysteine-less carrier was similar to that of the wild-type
AAC2 (20.2 1.2 versus 20.9 1.2 nmolmin1mg1 of AAC2),
confirming that the alanine substitutions did not affect the
function of the carrier (Fig. 2C). The introduction of a six-
histidine tag had no effect on function either, because the
average values in the absence of MTSES were 20.6  1.0 and
20.4  1.5 nmolmin1mg1 of AAC2 for untagged and tagged
AAC2, respectively. Wild-type AAC2 was inhibited fully by the
addition of MTSES, whereas cysteine-less AAC2 was unaffected
(Fig. 2C). The specific initial uptake transport rates of the
coexpressed Ppic2-XCLPpic2-HWT and Paac2-XCLPaac2-
HWT were reduced by the addition of MTSES to 90 and 78%,
respectively. The addition of MTSES affected coexpressed
Paac2-XWTPaac2-HCL and Ppic2-XWTPpic2-HCL to a
greater extent, leading to a reduction of transport rate to 39 and
30%, respectively. The residual transport activity correlated
linearly with the fraction of cysteine-less AAC2 present in the
membrane (Fig. 3). Therefore, the cysteine-less and wild-type
carriers functioned independently.
Reconstitution of Cysteine-Less and Wild-Type AAC2 in Defined Molar
Ratios. The cysteine-less AAC2 and wild-type AAC2 in complex
with ATR were purified separately in dodecylmaltoside, where
AAC2 is monomeric (28), mixed in a defined ratio and recon-
stituted into liposomes. After reconstitution of the carriers into
liposomes, ATRwas displaced with ADP. The specific initial rate
of uptake of ADP in the absence of MTSES was 16.4  4.6
nmolmin1mg1 of AAC2, which is slightly lower than the value
found for the carrier in mitochondrial membranes, and so the
reconstitution procedure was efficient. The slightly lower value
may be due to the loss of small amounts of functional material
during insertion, or to incomplete reversal of ATR inhibition or
to the lipid environment, not mimicking the mitochondrial
membrane. Again, the residual transport activity after addition
of MTSES correlated linearly with the fraction of cysteine-less
AAC2 that had been added to the mixture before reconstitution
(Fig. 3).
Discussion
Here, the possible association of the monomers of the yeast
ADP/ATP carrier AAC2 to form functional dimers was tested by
negative dominance studies. The approach exploits the sensitiv-
ity of the wild-type AAC2 to sulfhydryl reagents (35), and the
finding that the four cysteines in the wild-type AAC2 can be
replaced by alanine without affecting its activity. When the
cysteine-less and wild-type carriers were coexpressed in mito-
chondrial membranes, or mixed in defined ratios before being
reconstituted in liposomes, the residual transport rate after
addition of MTSES depended on the fraction of cysteine-less
carrier in the membrane in a linear way (Fig. 3). The residual
transport rates in the presence of MTSES fitted a power
function, according to Vwith MTSES  a  Fclb. The fitted values
were 102% and 1.03 for a and b, respectively, confirming that the
cysteine-less and wild-type AAC2 functioned independently.
The root mean square deviation was calculated between the
experimental data and the theoretical curves taking the data
points in the presence of MTSES (0	 Fcl	 1) (Fig. 3). The root
mean square deviation is 2.8% for functionally independent
carriers, which is within experimental error. In contrast, the root
mean square deviation would have been 13.1% if they had
functioned in a 1:1 dimer. Thus, the cysteine-less and wild-type
AAC2 function independently. It might be argued that the
results could be explained by homo-dimers of cysteine-less
AAC2 or homo-dimers of wild-type AAC2 forming preferen-
tially. For example, the presence of a His-tag could lead to the
dimerisation of this version exclusively. However, this possibility
was eliminated by the reconstitution experiments, in which both
the cysteine-less AAC2 and wild-type AAC2 were His-tagged. In
addition, if dimerisation by the His-tags occurred, it would have
to have been stronger than dimerisation by a protein–protein
interface, otherwise hetero-dimers of the two versions of AAC2
would have formed. However, then the specific transport rates
would be expected to be low as dimerisation required for
function would have been impaired (Fig. 2). Another possibility
was that if cysteines were involved in dimer formation, the
wild-type AAC2 might dimerize specifically to the exclusion of
the cysteine-less AAC2. However, because cysteine-less carriers
would be unable to dimerize, the specific uptake rate of the
cysteine-less carriers would be low. Also, the overall transport
rate of the coexpressed carriers would be negligible in the
presence of MTSES, because the cysteine-less carriers would be
unable to dimerize efficiently and the wild-type carriers would be
inhibited. The simplest explanation of our data is that the yeast
mitochondrial ADP/ATP carriers function as monomers rather
than dimers. This conclusion is consistent with its structure (13,
24) and the dimensions and molecular mass of the ADP/ATP
carrier in detergents (28).
Transporters of organic compounds vary considerably in size,
oligomeric state, and the position of the translocation pathway.
The TM domains of ABC transporters (10, but most commonly
six TM -helices) form dimers with the substrate transport
pathway at their interface (36–38). Members of the major
facilitator superfamily (12 TM -helices) consist of two struc-
Fig. 3. Correlation between the fraction of cysteine-less AAC2 and the
residual initial transport rate after addition of MTSES. The residual initial
transport rate in the presence of MTSES is expressed as a percentage of the
rate in the absence of MTSES. Open circles represent the residual rate of
coexpressed wild-type and/or cysteine-less AAC2 in mitochondrial mem-
branes. The average rate in the absence of MTSES (100%, dotted line) was
20.6  2.7 nmolmin1mg1 of AAC2 (raw data from Fig. 2). The closed
triangles indicate the residual transport rate of wild-type and/or cysteine-less
AAC2, purified separately and mixed in defined molar ratios and then recon-
stituted into liposomes. In this case, the average rate was 16.4  4.6
nmolmin1mg1 of AAC2 in the absence of MTSES (100%, dotted line). The
initial uptake rates of [14C]-ADP were determined in quintuplicate in the first
15 s of linear uptake. The amount of AAC2 in the fused mitochondrial
membranes or proteoliposomes was quantified in triplicate by usingWestern
blot analyses and known amounts of purified AAC2 as standard. The contin-
uous and dashed lines represent the theoretical correlation for the indepen-
dent and dependent functional interactions of the cysteine-less AAC2 and
wild-type AAC2, respectively.
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turally similar protein domains (each of six TM -helices)
through which the substrate passes (39–42). The minimal func-
tional unit for substrate binding in the multidrug transporter
EmrE (four TM -helices) is also a dimer with the substrate
binding at the monomer-monomer interface (43, 44). Aquapor-
ins and glycerol transporters (six TM -helices plus two half-
spanning -helices) are tetramers with a substrate translocation
pore in each monomer (45–47). The glutamate transporter
(eight TM -helices and two -helical hairpins) (48), the am-
monium channel (11 TM -helices) (49), and the multidrug
transporter AcrB (12 TM -helices) (50) are trimers, whereas the
leucine and aspartate transporters (10 TM -helices plus two
interrupted TM -helices) are dimers (51, 52), but each mono-
mer contains a substrate binding site.
In mitochondrial carriers the substrate is translocated via a
pathway in the middle of the structural fold of the protein, which
is formed by six TM -helices (13, 24, 53, 54). Therefore, the
ADP/ATP carrier is the smallest known functional transporter
unit, and yet its substrates ADP and ATP are among the largest
molecules that are actively transported across membranes. Other
members of the mitochondrial carrier family transport even
larger substrates like palmitoyl-carnitine (55, 56), CoA (57) or
S-adenosyl-methionine (58). The transport of these substrates
has to be achieved without any significant proton leak that would
uncouple ATP synthesis from the proton motive force. These
properties may explain why the mitochondrial ADP/ATP carrier
transports substrates at a relatively low rate compared with
members of other transporters families (59). Further studies into
the structural mechanism of the mitochondrial carriers are
required to understand how they accomplish this remarkable
feat.
Methods
Construction of Expression Vectors. A gene for the cysteine-less
AAC2 was constructed by replacing all cysteine codons in
wild-type aac2 by alanine codons by using PCR overlap exten-
sion with KOD polymerase (Novagen, Madison, WI and EMD
Biosciences, San Diego, CA). Vectors for the expression of the
His-tagged and untagged versions of the wild-type and cysteine-
less AAC2 as single proteins were based on the pYES-Ppic2-aac2
and pYES-Ppic2-His-aac2 vectors (28) or the pYES-Paac2-His-
aac2 and pYES-Paac2-aac2 vectors (60). To obtain vectors for
coexpression, the aac2 gene (wild-type or cysteine-less), pre-
ceded by the aac2 or pic2 promoter region and followed by a
transcription terminator, were introduced into the SpeI site at
the start of the promoter region in the pYES-Ppic2-His-aac2
vector or pYES-Paac2-His-aac2 vector, containing the second
type of aac2. SpeI sites were introduced by PCR with KOD
polymerase (Novagen) at both ends of the promoter-aac2-
transcription terminator cassette. Vectors and inserts were di-
gested with SpeI (New England BioLabs, Ipswich, MA). The
insert was ligated into the vector, and the vector was transformed
into Escherichia coli. Because the insert could be inserted in both
orientations, the desired version was identified by colony PCR
and sequencing (Geneservice, Cambridge, U.K.). The vector
containing the tandem expression cassette encoding wild-type
and cysteine-less AAC2 was transformed into the S. cerevisiae
strain WB-12 (MAT ade2-1 trp1-1 ura3-1 can1-100 aac1::LEU2
aac2::HIS3), lacking functional AAC1 and AAC2 carriers (21).
Preparation of Fused Mitochondrial Membranes for Transport Assays.
Yeast strains were grown as described in SI Methods and
mitochondrial membranes were prepared as described in ref. 60.
Liposomes were prepared with E. coli total lipid extract and egg
yolk phosphatidylcholine (Avanti Polar Lipids, Alabaster, IL)
mixed in a 3:1 (wt/wt) ratio in 50 mM potassium phosphate
buffer (KPi), pH 7.0, at a final lipid concentration of 20 mgml1.
Liposomes (5 mgml1) and mitochondrial membranes (1 mg of
protein ml1) were fused by mixing in 50 mM KPi, pH 7.0,
containing 5 mM ADP, followed by freezing in liquid nitrogen
and thawing at room temperature 7 times.
Inhibition and Purification of Yeast AAC2. Mitochondrial mem-
branes containing either wild-type or cysteine-less AAC2 were
diluted to 20 mgml1 with buffer, consisting of 0.65 M sorbitol
and 0.02MTrisHCl, pH 7.4. The membranes were incubated for
20 min at 4°C with ATR (Calbiochem, San Diego, CA and EMD
Biosciences, San Diego, CA) at a final concentration of 20
nmolmg1 of protein. Proteins were solubilized in 10 mM
TrisHCl (pH 7.4)/150 mM NaCl/10 mM imidazole/1% dodecyl-
-D-maltoside (Anatrace, Maumee, OH), and one tablet of
Complete protease inhibitors minus EDTA (Roche Diagnostics,
Mannheim, Germany) for 1 h at 4°C with stirring. Particulate
material was removed by ultracentrifugation at 140,000  g at
4°C for 45 min. The supernatant was passed through a nickel-
nitrilotriacetic acid Superflow (Qiagen, Valencia, CA) column
(flow rate, 0.5 mlmin1). The column was washed with 10 mM
TrisHCl (pH 7.4)/150 mM NaCl/0.05% dodecylmaltoside/5 M
ATR, containing first 40 mM and then 60 mM imidazole. The
carrier was eluted in the same buffer containing 200 mM
imidazole. The eluate was concentrated to 2 mgml1 in a YM-30
Centricon (Millipore, Billerica, MA) and purified on a Superdex
200 XK16/60 column (GE Healthcare, Little Chalfont, U.K.) in
buffer containing 10 mM TrisHCl (pH 7.4), 150 mM NaCl,
0.05% dodecylmaltoside, and 5 M ATR.
Reconstitution of Purified AAC2. Liposomes were prepared by using
E. coli total lipid extract and egg yolk phosphatidylcholine (Avanti
Polar Lipids) in a 3:1 (wt/wt) ratio in 50 mM KPi buffer, pH 7.0, at
a final lipid concentration of 20 mgml1. Liposomes were passed
nine times through a membrane with 1-m pores (Whatman,
Clifton, NJ) to make them unilamellar, and they were destabilized
withTritonX-100 (SIMethods). Purified carrier protein (20g) and
destabilized liposomes (10 mg) were added to 50 mM KPi buffer
(pH 7.0), with 0.2% (vol/vol) Triton X-100 and 5 mM ADP (3-ml
total volume), and the suspension was mixed. Detergent was
removed with Biobeads (240 mg) (Bio-Rad, Hercules, CA) and
gentle rotation for 2 h at 4°C. The Biobeads were removed by
filtration and the procedure was repeated twice more. The proteo-
liposomeswere collected by centrifugation at 300,000 g for 30min
at 4°C. The pellet was resuspended in KPi buffer containing 5 mM
ADP to a final volume of 1 ml.
Transport Assays. Proteoliposomes or fused membranes were
extruded 9 times in the presence of 5 mM ADP through a
membrane with 1-m pores (Whatman). When required, 3
mM MTSES (Anatrace) was added before extrusion. The
extruded membranes were harvested by centrifugation at
300,000  g for 30 min at 4°C. The pellet was resuspended in
KPi buffer containing 5 mM ADP. The external ADP was
removed on a Sephadex G-75 gel filtration column (3.5-ml bed
volume) equilibrated with KPi buffer. The proteoliposomes or
fused membranes were eluted in 1 ml of KPi buffer. Transport
was initiated by diluting 100 l of membranes in 300 l of KPi
buffer containing 1.35 M [8-14C]-ADP (Perkin–Elmer,
Waltham, MA). The experiments were performed at 12°C with
constant stirring. At intervals, the uptake of radio-labeled
substrate was quenched by adding ice cold KPi buffer (4 ml),
and immediately the mixture was filtered through cellulose
nitrate membranes (0.45 m pore size). The filters were
washed with ice-cold KPi buffer (2 ml), and incorporated
radioactivity was determined by scintillation counting. The
initial uptake rates of [14C]-ADP were determined in quintu-
plicate in the first 15 s of linear uptake. The amount of AAC2








in the fused mitochondrial membranes or proteoliposomes was
quantified in triplicate by using Western blot analyses and
known amounts of purified AAC2 as standard. The total
protein concentrations of the yeast mitochondrial membranes
were determined by the BCA protein assay kit (Pierce, Rock-
ford, IL) with BSA as standard. The sodium-dodecylsulfate
polyacrylamide gel electrophoresis and Western blot analysis
are described in SI Methods.
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